Guest, E. M., Kairalla, J. A., Devidas, M., Hibbitts, E., Carroll, A. J., Heerema, N. A., Kubaney, H. R., August, M. A., Ramesh, S., Yoo, B., Farooqi, M. S., Pauly, M. G., Wechsler, D. S., Miles, R. R., Reid, J. M., Kihei, C. D., Gore, L., Raetz, E. A., Hunger, S. P., Loh, M. L. and Brown, P. A. (2020) “Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed <i>KMT2A</i&gt;-rearranged acute lymphoblastic leukemia: Children’s Oncology Group trial AALL15P1”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2024.285158.